Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma

Journal of the National Cancer Institute

Volumn 88, Issue 17, 1996, Pages 1228-1233

  Bourhis, Jean ^a   Lubin, Richard ^b   Roche, Béatrice ^a   Koscielny, Serge ^a   Bosq, Jacques ^a   Dubois, Isabelle ^b   Talbot, Monique ^a   Marandas, Patrick ^a   Schwaab, Guy ^a   Wibault, Pierre ^a   Luboinski, Bernard ^a   Eschwege, François ^a   Soussi, Thierry ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UF de Génétique Moléculaire HÔpital Lariboisière   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN ANTIBODY; PROTEIN P53; PROTEIN P53 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; FEMALE; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

EID: 9544237176     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.17.1228     Document Type: Article

References (44)

1. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 1994;57:1-9.
2. Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL, Casey G. Frequent p53 mutations in head and neck cancer. Cancer Res 1992;52:5997-6000.
3. Sakai E, Tsuchida N. Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene 1992;7:927-33.
4. Ahomadegbe JC, Barrois M, Fogel S, Le Bihan ML, Douc-Rasy S, Duvillard P, et al. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995;10:1217-27.
5. Brachman DG, Graves D, Yokes E, Beckett M, Haraf D, Montag A, et al. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res 1992;52:4832-6.
6. Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:712-7.
7. Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993;53: 4477-80.
8. Yin XY, Smith ML, Whiteside TL, Johnson JT, Herberman RB, Locker J. Abnormalities in the p53 gene in tumors and cell lines of human squamous-cell carcinomas of the head and neck. Int J Cancer 1993;54;322-7.
9. Watling DL, Gown AM, Coltrera MD. Over-expression of p53 in head and neck cancer. Head Neck 1992;14:437-44.
10. Field JK, Spandidos DA, Stell PM. Overexpression of p53 gene in head-and-neck cancer, linked with heavy smoking and drinking [letter]. Lancet 1992;339:502-3.
11. Sauter ER, Cleveland D, Track B, Ridge JA, Klein-Szanto AJ. p53 is overexpressed in fifty percent of pre-invasive lesions of head and neck epithelium. Carcinogenesis 1994;15:2269-74.
12. Shin DM, Lee JS, Choi G, Shah T, Hyne K, Earley C, et al. Prognostic significance of p53 expression in squamous cell carcinoma. Proc ASCO 1994;13:283.
13. Bourhis J, Bosq J, Wilson GD, Bressac B, Talbot M, Leridant AM, et al. Correlation between p53 gene expression and tumor-cell proliferation in oropharyngeal cancer. Int J Cancer 1994;57:458-62.
14. Frank JL, Bur ME, Garb JL, Kay S, Ware JL, Sismanis A, et al. p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx. Cancer 1994;73:181-6.
15. Gasparini G, Weidner N, Maluta S, Pozza F, Boracchi P, Mezzetti M, et al. Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int J Cancer 1993; 55:739-44.
16. Nylander K, Stenling R, Gustafsson H, Zackrisson B, Roos G. p53 expression and cell proliferation in squamous cell carcinomas of the head and neck. Cancer 1995;75:87-93.
17. Caron de Fromentel C, May-Levin F, Mouriesse H, Lemerle J, Chandrasekaren K, May P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer 1987;39:185-9.
18. Preudhomme C, Lubin R, Lepelley P, Vanrumbeke M, Fenaux P. Detection of serum anti p53 antibodies and their correlation with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 1994;8: 1589-91.
19. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Many M, Lane D, et al. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992;52:6380-4.
20. Wild CP, Ridanpaa M, Anttila S, Lubin R, Soussi T, Husgafvel-Pursiainen K, et al. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. Int J Cancer 1995;64:176-81.
21. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992;52:4168-74.
22. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci U S A 1992;89:3439-42.
23. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982;30:403-8.
24. Volkmann M, Muller M, Hofmann WJ, Meyer M, Hagelstein J, Rath U, et al. The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the alpha-fetoprotein status. Hepatology 1993;18:559-65.
25. Laurent-Puig P, Lubin R, Semhoun-Ducloux S, Pelletier G, Fourre C, Ducreux M, et al. Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. Gut 1995;36:455-8.
26. Marxsen J, Schmiegel W, Roder C, Harder R, Juhl H, Henne-Bruns D, et al. Detection of the anti-p53 antibody response in malignant and benign pancreatic disease. Br J Cancer 1994; 70:1031-4.
27. Labrecque S, Naor N, Thomson D, Matlashewski G. Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 1993; 53:3468-71.
28. Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994;58:480-7.
29. Lubin R, Schlichtholz B, Teillaud JL, Dubois I, Bengoufa D, Soussi T. p53 antibodies in patients with various types of cancer: assay, identification and characterization. Clin Cancer Res. In press.
30. Schlichtholz B, Tredaniel J, Lubin R, Zalcman G, Hirsch A, Soussi T. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 1994;69:809-16.
31. Legros Y, Lafon C, Soussi T. Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein. Oncogene 1994;9:2071-6.
32. Cough MJ, Koch M, Brennan JA, Sidransky D. The humoral response to oncoprotein p53 in head and neck cancer. Head Neck 1994; 16:495.
33. Peyrat JP, Bonneterre J, Lubin R, Vanlemmens L, Fournier J, Soussi T. Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 1995;345:621-2.
34. Bourhis J, Wilson G, Wibault P, Bosq J, Chavaudra N, Janot F, et al. In vivo measurement of the potential doubling time by flow-cytometry in oropharyngeal cancer treated by conventional radiotherapy. Int J Radiat Oncol Biol Phys 1993;26:793-9.
35. Bourhis J, Fortin A, Dupuis O, Domenge C, Lusinchi A, Marandes P, et al. Very accelerated radiotherapy: preliminary results in locally unresectable head and neck carcinomas [see comment citation in Medline]. Int J Radiat Oncol Biol Phys 1995;32:747-52.
36. Bourhis J, Wilson G, Wibault P, Janot F, Bosq J, Armand JP, et al. Rapid tumor cell proliferation after induction chemotherapy in oropharyngeal cancer. Laryngoscope 1994;104: 468-72.
37. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A 1972;135:185-207.
38. Metha CR, Patel NR. A network algorithm for performing Fisher's exact test in r x c contingency tables. J Am Stat Assoc 1983;78:427-34.
39. Guinee D, Travis W, Trivers G, Debenedetti V, Cawley H, Welsh J. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and c-erbB2 expression. Carcinogenesis 1995;16:993-1002.
40. Lubin R, Schlichtholz B, Bengoufa D, Zalcman G, Tredaniel J, Hirsch A, et al. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 1993;53:5872-6.
41. Pavelic ZP, Gluckman JL, Gapany M, Reising J, Craven JM, Kelley DJ, et al. Improved immunohistochemical detection of p53 protein in paraffin-embedded tissues reveals elevated levels in most head and neck and lung carcinomas: correlation with clinicopathological parameters. Anticancer Res 1992;12:1389-94.
42. Winter SF, Sekido Y, Minna JD, McIntire D, Johnson BE, Gazdar AF, et al. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival [see comment citation in Medline]. J Natl Cancer Inst 1993;85:2012-8.
43. Ory K, Legros Y, Auguin C, Soussi T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 1994;13:3496-504.
44. Merlo GR, Bernardi A, Diella F, Vanesio T, Cappa AP, Callahan R, et al. In primary human breast carcinomas mutations in exons 5 and 6 of the p53 gene are associated with a high S-phase index. Int J Cancer 1993;54:531-5.